Join to view full profile
9300 Euclid AvenueF20Cleveland, OH 44106
Dr. Caramori is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Luiza Caramori is an endocrinologist at Cleveland Clinic in OH. She is also an Adjunct Associate Professor at the University of Minnesota. Dr. Caramori received her medical degree from Federal University of Rio Grande do Sul School of Medicine, completed over 14 years of training after medical school, including residency, fellowships, Masters, PhD and Post-PhD. She has been in practice for 32 years. Dr. Caramori speaks multiple languages, including Portuguese. She is a clinician-scientistist funded by NIH, and an internationally recognized expert in diabetic kidney disease. Her clinical interest focuses on diabetic kidney disease, type 1 diabetes, and type 2 diabetes. She provides outstanding care to her patients.
Education & Training
University of MinnesotaFellowship, Endocrinology, Diabetes, and Metabolism, 2004 - 2006
Federal University of Rio Grande do Sul School of MedicineClass of 1990
Certifications & Licensure
OH State Medical License 2022 - 2028
MN State Medical License 2006 - 2023
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
- Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease Start of enrollment: 2015 Sep 17
- Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease Start of enrollment: 2015 Sep 17
Publications & Presentations
PubMed
- Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status.Ricardo Correa-Rotter, Peter Rossing, Maria Eugenia Canziani, Maria Luiza Caramori, David Cherney
Kidney International Reports. 2026-07-01 - Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses.David Z I Cherney, Peter Rossing, Maria Eugenia Canziani, Maria Luiza Caramori, Ricardo Correa-Rotter
Diabetes, Obesity & Metabolism. 2026-07-01 - 1 citationsCumulative Effects of Vicadrostat and Empagliflozin on Albuminuria in CKD.Peter Rossing, Sibylle J Hauske, Maria Eugenia Canziani, Maria Luiza Caramori, David Z I Cherney
American Journal of Kidney Diseases. 2026-05-01
Press Mentions
U of M Awarded $2.5M in NIH Funding for Minnesota Site of Kidney Precision Medicine ProjectNovember 3rd, 2022
Professional Memberships
- Chair - Diabetic Nephropathy Subcommittee for the ADA Annual Scientific Sessions 2018-2020
- Member
- Member
- European Diabetic Nephropathy Study GroupMember
Other Languages
- Portuguese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
